Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03823703 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Corcept Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03823703 is a Phase 2 study that was terminated before completion, run by Corcept Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT03823703, a Phase 2 study, was terminated before completion, sponsored by Corcept Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).
Interventions
- DRUG Placebo
- DRUG Miricorilant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-11-04 |
| Est. Completion | 2021-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03823703
The ClinicalTrials.gov registry entry for NCT03823703 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03823703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03823703 about?
NCT03823703 is a clinical study titled "Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)". This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).
What is the current status of trial NCT03823703?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2020-11-04. Estimated completion is 2021-04-05.
What interventions are being tested in trial NCT03823703?
The interventions under investigation include: Placebo (DRUG), Miricorilant (DRUG).
Who is sponsoring clinical trial NCT03823703?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.